MedTrace Logo

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

NCT05200936 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2026-02-27

Study results available
· View outcomes & findings →

Summary

This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled

Conditions

  • ADHD
  • Attention Deficit Disorder

Interventions

DRUG

MM120

MM120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM120 manifests primarily visual, as well as auditory, hallucinations.

OTHER

Placebo

A treatment which is designed to have no therapeutic value.

Sponsors & Collaborators

  • Definium Therapeutics US, Inc.

    lead INDUSTRY

Principal Investigators

  • Kim Kuypers · Maastricht University

  • Matthias Liechti · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-17
Primary Completion
2023-11-06
Completion
2023-12-04

Countries

  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200936 on ClinicalTrials.gov